UCB's $2.2B Candid Buyout: Game-Changer for Immunology episode artwork

EPISODE · May 4, 2026 · 1 MIN

UCB's $2.2B Candid Buyout: Game-Changer for Immunology

from The Daily News Now! Business

UCBs $2.2 billion acquisition of Candid Therapeutics brings a promising bispecific antibody, cizutamig, to their pipeline, targeting autoimmune and inflammatory diseases. The deal, expected to close in Q2 or Q3, includes an additional $200 million if milestones are met. UCBs CEO hails it as a game-changer, while Candids head praises UCBs immunology expertise. The acquisition aligns with UCBs strategy to strengthen their next-gen immunology portfolio. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6a1d0e80f312d590

NOW PLAYING

UCB's $2.2B Candid Buyout: Game-Changer for Immunology

0:00 1:38

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Daily News Now! Business?

This episode is 1 minute long.

When was this The Daily News Now! Business episode published?

This episode was published on May 4, 2026.

What is this episode about?

UCBs $2.2 billion acquisition of Candid Therapeutics brings a promising bispecific antibody, cizutamig, to their pipeline, targeting autoimmune and inflammatory diseases. The deal, expected to close in Q2 or Q3, includes an additional $200...

Can I download this The Daily News Now! Business episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!